Another study examining Yes-associated protein (YAP) [69] found that inhibiting PFKFB3 by inhibiting YAP prevented pathological angiogenesis and metabolic abnormalities and reduced the degree of retinopathy, demonstrating that targeting YAP with PFKFB3 may be a potential target for the treatment of neovascular retinal diseases. This evidence concerns the gene PFKFB3 and retinal disorder.